2-Chloro-5-(2-ethoxyvinyl)pyrimidin-4-amine | 1190862-45-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-Chloro-5-(2-ethoxyvinyl)pyrimidin-4-amine
• 英文别名: 2-chloro-5-[(E)-2-ethoxyethenyl]pyrimidin-4-amine
• CAS: 1190862-45-3
• 化学式: C₈H₁₀ClN₃O
• 分子量: 199.64
• InChiKey: PZGLKKDFPIMFAL-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氨基-5-溴-2-氯嘧啶 、 三丁基(2-乙氧基乙烯基)锡 在 catalyst 、 四(三苯基膦)钯 hexanes 、 hexanes ethyl acetate 作用下， 以 甲苯 为溶剂， 反应 64.0h， 以to give the title compound (0.70 g, 32%) as a white solid的产率得到2-Chloro-5-(2-ethoxyvinyl)pyrimidin-4-amine
  参考文献：
  名称：

  SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS

  摘要：

  本公开涉及新的p38丝裂原活化蛋白激酶抑制剂，其具有一般式(I)，其制备方法，其药物组合物以及其使用方法。

  公开号：

  US20110053936A1

文献信息

• New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2108641A1

  公开（公告）日：2009-10-14

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• [EN] COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS<br/>[FR] COMPOSÉS PERMETTANT DE RÉGULER LES VOIES FAK ET/OU SRC
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038417A1

  公开（公告）日：2015-03-19

  The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的可选择替代的融合吡啶和嘧啶双环化合物及其药用可接受盐。还提供了制备这些化合物的方法。通过向受试者投予一种或多种化合物的治疗有效量，这些化合物在共调节FAK和/或Src活性方面具有用处。通过这样做，这些化合物在治疗与FAK和/或Src途径失调相关的疾病方面具有有效性。这些化合物作为双重FAK和/或Src抑制剂表现出优势。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS
  申请人：ARIAD PHARMACEUTICALS, INC.

  公开号：US20150225436A1

  公开（公告）日：2015-08-13

  The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  该发明涉及一般式化合物：其中变量基团如本文所定义，以及它们的制备和使用。
• [EN] PPAR ACTIVE COMPOUNDS<br/>[FR] COMPOSES AYANT UNE ACTIVITE SUR DES PPAR
  申请人：PLEXXIKON INC

  公开号：WO2005009958A1

  公开（公告）日：2005-02-03

  Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

  描述了对PPARs具有活性的化合物，包括全活性化合物。还描述了开发或识别具有所需选择性配置文件的化合物的方法。
• PPAR active compounds
  申请人：Arnold James

  公开号：US20050288354A1

  公开（公告）日：2005-12-29

  Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

  描述了对PPARs活性的化合物，包括全活性化合物。还描述了开发或识别具有所需选择性配置文件的化合物的方法。